DT&CRO Co

DT&CRO Co Capital Expenditures

The Capital Expenditures (CapEx) of DT&CRO Co (383930.KQ) as of Oct 20, 2026 is -19.29 B KRW. In the previous year, Capital Expenditures (CapEx) was -14.87 B KRW — a change of 29.74% (lower).

Capital Expenditures

-19.29 BKRW

YoY

29.74%

Last updated:

Capital Expenditures (CapEx) of DT&CRO Co is 2024 -19.29 B KRW. Capital Expenditures (CapEx) of DT&CRO Co was 2023 -14.87 B KRW. It decreases by 29.74% lower compared to the previous year.

The DT&CRO Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-3.38 B KRW
Jan 1, 2020
-3.09 B KRW
Jan 1, 2022
-14.87 B KRW
Jan 1, 2024
-19.29 B KRW
The DT&CRO Co Capital Expenditures history
YEARCapital ExpendituresYoY
-19.29 BKRW+29.74%
-14.87 BKRW+381.60%
-3.09 BKRW-8.56%
-3.38 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DT&CRO Co Stock analysis

What does DT&CRO Co do? DT&CRO Co Ltd is a South Korean company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Based in Yongin, the company has 277 employees and completed its initial public offering (IPO) on November 11, 2022. DT&CRO Co Ltd provides non-clinical and clinical trial services for pharmaceuticals, medical devices, food, chemicals, and cosmetics. The company also offers analysis, efficacy evaluation, and related services. Its headquarters are located in Yongin, Gyeonggi-Do, South Korea. The company's website is www.dtncro.com. DT&CRO Co Ltd is engaged in research and development activities related to medicine and pharmaceuticals, though specific details about its R&D focus or product offerings are not provided in the available information. The company operates as a service provider in the life sciences sector, supporting various industries through trial services and analytical solutions. As a publicly traded company, it is listed under the ticker symbol 383930.KQ with ISIN KR7383930005. The company's operations are centered on delivering specialized services to clients in the pharmaceutical and related industries, emphasizing both non-clinical and clinical trial support. DT&CRO Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DT&CRO Co stock

Capital Expenditures (CapEx) of DT&CRO Co is -19.29 B KRW in 2024.

Capital Expenditures (CapEx) of DT&CRO Co changed from -14.87 B KRW to -19.29 B KRW, representing a 29.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) DT&CRO Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s DT&CRO Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — DT&CRO Co

All Key Metrics — DT&CRO Co